An international consortium led by Crucell NV of the Netherlands has received a contract valued at up to $70 million from the US National Institutes of Allergy and Infectious Diseases (NIAID) to develop a multivalent vaccine against the Ebola and Marburg viruses. The NIAID is part of the National Institutes of Health (NIH), one of the world’s largest funders of medical research.
